Vericel Corp (NAS:VCEL)

$ 48.23 0.24 (0.5%) Market Cap: 2.34 Bil Enterprise Value: 2.33 Bil PE Ratio: 9,999.00 PB Ratio: 10.00 GF Score: 82/100

Q1 2024 Vericel Corp Earnings Call Transcript
May 08, 2024

$47.69 (-3.70%)

Earnings
Q4 2023 Vericel Corp Earnings Call Transcript
Feb 29, 2024

$45.68 (-4.44%)

Earnings
Vericel Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Vericel Corp Earnings Call Transcript
Nov 08, 2023

$35.27 (-3.40%)

Earnings
Vericel Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Vericel Corp Earnings Call Transcript
Aug 02, 2023

$34.63 (-1.40%)

Earnings
Q1 2023 Vericel Corp Earnings Call Transcript
May 10, 2023

$34.19 (+4.11%)

Earnings
Q4 2022 Vericel Corp Earnings Call Transcript
Feb 23, 2023

$30.6 (+7.29%)

Earnings
Vericel Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Vericel Corp Earnings Call Transcript
Nov 09, 2022

$17.65 (-23.43%)

Earnings
Q2 2022 Vericel Corp Earnings Call Transcript
Aug 03, 2022

$31.73 (-0.25%)

Earnings
Q1 2022 Vericel Corp Earnings Call Transcript
May 04, 2022

$31.05 (-0.99%)

Earnings
Q4 2021 Vericel Corp Earnings Call Transcript
Feb 24, 2022

$38.88 (+20.82%)

Earnings
Vericel Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Q3 2021 Vericel Corp Earnings Call Transcript
Nov 09, 2021

$42.15 (-2.20%)

Earnings
Vericel Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Q2 2021 Vericel Corp Earnings Call Transcript
Aug 04, 2021

$49.18 (-4.91%)

Earnings
Vericel Corp at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Vericel Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Q1 2021 Vericel Corp Earnings Call Transcript
May 05, 2021

$56.59 (-4.33%)

Earnings
Vericel Corp Annual Shareholders Meeting Transcript
Apr 28, 2021
Q4 2020 Vericel Corp Earnings Call Transcript
Feb 24, 2021

$49.45 (+4.39%)

Earnings
Vericel Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Vericel Corp at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2020
Q3 2020 Vericel Corp Earnings Call Transcript
Nov 05, 2020

$21.73 (+2.50%)

Earnings
Vericel Corp Corporate Analyst Meeting Transcript
Oct 16, 2020
Vericel Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Vericel Corp Earnings Call Transcript
Aug 05, 2020

$15.92 (-5.35%)

Earnings
Vericel Corp at UBS Global Healthcare Conference (Virtual) Transcript
May 20, 2020
Q1 2020 Vericel Corp Earnings Call Transcript
May 05, 2020

$14.42 (+2.85%)

Earnings
Q4 2019 Vericel Corp Earnings Call Transcript
Feb 25, 2020

$16.69 (-11.65%)

Earnings
Vericel Corp at Needham Growth Conference Transcript
Jan 15, 2020
Q3 2019 Vericel Corp Earnings Call Transcript
Nov 05, 2019

$18.34 (+12.86%)

Earnings
Vericel Corp at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Q2 2019 Vericel Corp Earnings Call Transcript
Aug 06, 2019

$18.6 (+5.14%)

Earnings
Vericel Corp at UBS Global Healthcare Conference Transcript
May 22, 2019
Q1 2019 Vericel Corp Earnings Call Transcript
May 07, 2019

$17.3 (-5.98%)

Earnings

Vericel Corp at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 03:30PM GMT

Release Date Price: $27.62 (-0.40%)

Transcript 8-K

Unidentified Analyst

Good morning. Welcome, everyone, to the third day of the 41st JPMorgan Conference. Here we go. We're thrilled to have you here, and we're thrilled to have the Vericel team as well. We've got Nick Colangelo, President and CEO, here to present. I'll go ahead and pass it over to Nick.

Dominick C. Colangelo

Vericel Corporation - CEO, President & Director

Okay. Well, thanks, [James]. It's great to be here today. And before I begin, I just want to remind everyone that this presentation contains forward-looking statements, and you should refer to our documents on file with the SEC for further information.

So for those of you who are not as familiar with our company, Vericel is a leader in advanced therapies for the sports medicine and the severe burn care markets. We have a portfolio of highly innovative advanced cell therapies and specialty biologics that are really focused on changing the standard of care for patients with cartilage injuries and severe burns.

We currently market 2 products in the United States. They're both

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.